

10-22-1998

US DEPARTMENT OF COMMERCE  
Patent and Trademark Office

FR SHEET

-Y

100858007

To the Honorable Commiss

he attached original documents or copy thereof.

## 1. Name of conveying party(ies):

**Michael Dennis DOWLE, Harry FINCH, Lee Andrew HARRISON,  
Graham George Adam INGLIS, Martin Redpath JOHNSON,  
Simon John FAWCETT MACDONALD, Pritom SHAH and Robin  
Andrew SMITH**Additional name(s) of conveying party(ies) attached? Yes  
No

## 3. Nature of conveyance:

**X Assignment**

Merger

Security Agreement

Change of Name

Other \_\_\_\_\_

10.13.98

## 2. Name and address of receiving party(ies):

Name: **GLAXO WELLCOME INC.**  
Internal Address: **Global Intellectual Property**  
Dept. **333**  
Street Address: **5 Moore Drive**  
**PO Box 13398**  
City: **Research Triangle Park**  
State: **NC**  
Zip: Code: **27709-3398**Additional name(s) & address(es) attached? YES

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No.(s)

B. Patent No.(s)

**PCT/EP97/01530 filed on 26 March 1997**additional numbers attached? Yes X No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **David J. Levy**  
Internal Address: **Glaxo Wellcome Inc.**  
**Global Intellectual Property**  
Street Address: **Five Moore Drive**  
**PO Box 13398**  
City: **RTP** State: **NC** Zip: **27709**6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): .....\$40.00

**X Authorized to be charged to deposit account**

8. Deposit account number: 07-1392

DO NOT USE THIS SPACE

## 9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

James P. RIEK

Signature

Oct. 98  
DateTotal number of pages comprising cover sheet: 1 of 1

10/21/1998 SBRMS 00000079 071392 PCTEP9701530

01 FC:501

40.00 CH

PATENT  
REEL: 9518 FRAME: 0755

## ASSIGNMENT

WHEREAS I/WE, Michael Dennis DOWLE, Harry FINCH, Lee Andrew HARRISON, Graham George Adam INGLIS, Martin Redpath JOHNSON, Simon John Fawcett MACDONALD, Pritom SHAH and Robin Andrew SMITH all residing at c/o Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, GB (hereinafter called "the inventor(s)") have invented or discovered "Pyrrolopyrrolone Derivatives as Inhibitors of Neutrophil Elastase" (hereinafter called "the invention") for which an application for Letters Patent in the United States of America was originally filed as International Application No. PCT/EP97/01530 on 26 March 1997 (hereinafter called "the application"), and

WHEREAS the invention, being made in the circumstances set out in Section 39(1)(a) of the United Kingdom Patents Act 1977, belongs to my/our employer, namely GLAXO WELLCOME plc, a company incorporated in England whose registered address is Lansdowne House, Berkeley Square, London W1X 6BQ, England, and

WHEREAS GLAXO RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, is desirous of acquiring from GLAXO WELLCOME plc the whole right, title and interest in and to the invention and the application, and

WHEREAS GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO WELLCOME INC., a corporation organised and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA is desirous of acquiring from GLAXO RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

**NOW, THEREFORE**, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXO WELLCOME plc** of the invention and the application by operation of law under the United Kingdom Patents Act 1977 and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXO WELLCOME plc**. **GLAXO WELLCOME plc** in turn hereby assigns and transfers to **GLAXO RESEARCH AND DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. **GLAXO RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO WELLCOME INC.** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXO WELLCOME plc** and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **GLAXO WELLCOME INC.**

**AND GLAXO WELLCOME plc** and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO WELLCOME INC.**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from the 28th day of March 1996 the inventor(s) and Graham George Brereton as Attorney of both **GLAXO WELLCOME plc** and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** by virtue of Powers of Attorney granted by **GLAXO WELLCOME plc** and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** respectively have hereunto set their respective hands.

SIGNED by Michael Dennis DOWLE:

*Michael Dennis Dowle*

in the presence of:

*P. W. Smith*

SIGNED by Harry FINCH:

*Harry Finch*

In the presence of:

*Stuart*

SIGNED by Lee Andrew HARRISON:

*Lee Andrew Harrison*

In the presence of:

*Broome*

SIGNED by Graham George Adam INGLIS:

*Graham George Adam Inglis*

in the presence of:

*Carol Mills*

SIGNED by Martin Redpath JOHNSON:

*Martin Redpath Johnson*

In the presence of:

*Alan John William Stewart*

SIGNED by Simon John Fawcett MACDONALD:

*Simon John Fawcett Macdonald*

In the presence of:

*DDM*

SIGNED by Pritom SHAH:

*Pritom Shah*

In the presence of:

*Geoffrey Clarke*

SIGNED by Robin Andrew SMITH:

*Robin Andrew Smith*

In the presence of:

*DDHumpney*

SIGNED by Graham George Brereton as the Attorney of each of Glaxo Wellcome plc  
and Glaxo Research and Development Limited:

*Graham George Brereton*